PE20150666A1 - Inhibidores de serina/treonina cinasa - Google Patents

Inhibidores de serina/treonina cinasa

Info

Publication number
PE20150666A1
PE20150666A1 PE2014001344A PE2014001344A PE20150666A1 PE 20150666 A1 PE20150666 A1 PE 20150666A1 PE 2014001344 A PE2014001344 A PE 2014001344A PE 2014001344 A PE2014001344 A PE 2014001344A PE 20150666 A1 PE20150666 A1 PE 20150666A1
Authority
PE
Peru
Prior art keywords
serine
kinase inhibitors
threonine kinase
compounds
hyperproliferative
Prior art date
Application number
PE2014001344A
Other languages
English (en)
Inventor
James F Blake
Mark Joseph Chicarelli
Rustam Ferdinand Garrey
John Gaudino
Jonas Grina
David A Moreno
Peter J Mohr
Li Ren
Jacob Schwarz
Huifen Chen
Kirk Robarge
Aihe Zhou
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of PE20150666A1 publication Critical patent/PE20150666A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La invencion describe compuestos de formula l: o estereoisomeros, tautomeros, profarmacos o sales farmaceuticamente aceptables de los mismos, en la que R1, R2, R3, R4, X1, X2, Y1 y Y2 se definen en la presente solicitud. Estos compuestos son activos como inhibidores de serina/treonina cinasa, por lo que son utiles en el tratamiento de enfermedades hiperproliferativas e inflamatorias.
PE2014001344A 2012-03-01 2013-03-01 Inhibidores de serina/treonina cinasa PE20150666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605523P 2012-03-01 2012-03-01

Publications (1)

Publication Number Publication Date
PE20150666A1 true PE20150666A1 (es) 2015-05-06

Family

ID=47892024

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001344A PE20150666A1 (es) 2012-03-01 2013-03-01 Inhibidores de serina/treonina cinasa

Country Status (36)

Country Link
US (4) US8697715B2 (es)
EP (2) EP2820009B1 (es)
JP (2) JP6068515B2 (es)
KR (1) KR102093526B1 (es)
CN (2) CN104507926B (es)
AR (2) AR090220A1 (es)
AU (1) AU2013225737B2 (es)
BR (1) BR112014021634B1 (es)
CA (1) CA2866086C (es)
CL (1) CL2014002301A1 (es)
CO (1) CO7081155A2 (es)
CR (1) CR20140413A (es)
CY (1) CY1120172T1 (es)
DK (2) DK2820009T3 (es)
ES (2) ES2857649T3 (es)
HK (3) HK1204323A1 (es)
HR (2) HRP20180591T1 (es)
HU (2) HUE053994T2 (es)
IL (2) IL234376A (es)
LT (2) LT2820009T (es)
MX (1) MX354675B (es)
MY (1) MY191936A (es)
NO (1) NO2945854T3 (es)
NZ (1) NZ700314A (es)
PE (1) PE20150666A1 (es)
PH (3) PH12014501947B1 (es)
PL (2) PL2820009T3 (es)
PT (2) PT2820009T (es)
RS (2) RS57097B1 (es)
RU (1) RU2650501C2 (es)
SG (1) SG11201405356QA (es)
SI (2) SI2820009T1 (es)
TW (1) TWI589569B (es)
UA (1) UA116774C2 (es)
WO (1) WO2013130976A1 (es)
ZA (2) ZA201406688B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543050T3 (es) 2011-02-28 2015-08-14 Array Biopharma, Inc. Inhibidores de serina/treonina quinasa
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
KR102093526B1 (ko) * 2012-03-01 2020-03-25 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제
EP2844652B1 (en) * 2012-05-03 2019-03-13 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
WO2014036015A1 (en) 2012-08-27 2014-03-06 Array Biopharma Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
DK3063143T3 (en) 2013-11-01 2018-08-20 Novartis Ag Amino heteroaryl benzamides as kinase inhibitors
MX368443B (es) * 2013-12-06 2019-10-02 Genentech Inc Inhibidores de serina/treonina cinasa.
CA2934709C (en) 2013-12-30 2022-08-30 Array Biopharma Inc. Serine/threonine kinase inhibitors
KR102379517B1 (ko) * 2013-12-30 2022-03-25 제넨테크, 인크. 세린/트레오닌 키나아제 억제제
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
MX2016013162A (es) * 2014-04-09 2017-04-27 Genentech Inc Proceso para la fabricacion de medicamentos.
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
ES2700200T3 (es) * 2014-12-22 2019-02-14 Lilly Co Eli Inhibidores de ERK
US10238657B2 (en) * 2015-06-03 2019-03-26 Js Innopharm (Shanhai) Ltd. Heterocyclic compounds for treating psoriasis
WO2016192063A1 (en) * 2015-06-03 2016-12-08 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as erk inhibitors
AU2016341520C1 (en) 2015-10-21 2021-07-22 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2017070708A1 (en) * 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
RS60155B1 (sr) 2015-11-09 2020-05-29 Astrazeneca Ab Derivati dihidroimidazopirazinona korisni za upotrebu u tretmanu raka
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3998261A1 (en) 2016-06-16 2022-05-18 Denali Therapeutics Inc. Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
EP3672973A4 (en) * 2017-08-22 2021-05-26 JS Innopharm (Shanghai) Ltd. HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
EP3679159A1 (en) 2017-09-08 2020-07-15 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
EP3713927B1 (en) 2017-11-24 2021-12-15 Novartis AG Pyridinone derivatives and their use as selective alk-2 inhibitors
CN111683928B (zh) * 2018-02-08 2021-12-10 漳州片仔癀药业股份有限公司 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
SG11202011513RA (en) * 2018-05-22 2020-12-30 Js Innomed Holdings Ltd Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
US20220213119A1 (en) * 2019-03-28 2022-07-07 Jiangsu Hengrui Medicine Ca, Lid. Thienoheterocyclic derivative, preparation method therefor and medical use thereof
CN113784970B (zh) * 2019-05-15 2022-11-29 南京明德新药研发有限公司 Erk抑制剂及其应用
WO2021025407A1 (ko) 2019-08-02 2021-02-11 웰마커바이오 주식회사 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물
WO2022100586A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672035A1 (en) 1993-10-01 1995-09-20 Novartis AG Pyrimidineamine derivatives and processes for the preparation thereof
WO1995009851A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO1998024780A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
PL203805B1 (pl) 2000-02-25 2009-11-30 Hoffmann La Roche Zastosowanie cyklicznych związków heteroaromatycznych, lek i cykliczne związki heteroaromatyczne
KR20070058022A (ko) 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물
EP1280771B1 (de) 2000-05-02 2004-10-13 Tietze, Lutz F., Prof. Dr. Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo 3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo f]chinolin-derivaten für eine selektive krebstherapie
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (es) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
WO2003057689A1 (en) * 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
CN100486576C (zh) * 2002-02-14 2009-05-13 法玛西雅公司 作为p38map激酶调节剂的取代吡啶酮类
WO2003099808A1 (en) 2002-05-21 2003-12-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
DE60330485D1 (de) 2002-07-15 2010-01-21 Merck & Co Inc Zur behandlung von diabetes
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
NL1026826C2 (nl) * 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
ATE485824T1 (de) 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP1786781A2 (en) 2004-08-27 2007-05-23 GPC Biotech AG Pyrimidine derivatives
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
ATE485268T1 (de) 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
CA2661334C (en) 2006-08-23 2011-11-29 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
MX2009008271A (es) 2007-02-01 2009-08-12 Tibotec Pharm Ltd Procesos e intermediarios para la preparacion de un inhibidor de proteasa macrocilico del vhc.
KR20100020454A (ko) 2007-06-08 2010-02-22 바이엘 크롭사이언스 소시에떼아노님 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
US8530480B2 (en) 2007-09-04 2013-09-10 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
KR20100088150A (ko) 2007-11-06 2010-08-06 이 아이 듀폰 디 네모아 앤드 캄파니 살진균성 복소환식 아민
JP5276676B2 (ja) 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である化合物
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
PE20110136A1 (es) 2008-06-27 2011-03-17 Novartis Ag Compuestos organicos
PT2370413E (pt) * 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
DE102009051799B4 (de) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
JPWO2012020786A1 (ja) * 2010-08-11 2013-10-28 日本新薬株式会社 医薬組成物
ES2543050T3 (es) 2011-02-28 2015-08-14 Array Biopharma, Inc. Inhibidores de serina/treonina quinasa
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
KR102093526B1 (ko) * 2012-03-01 2020-03-25 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제
WO2014036015A1 (en) 2012-08-27 2014-03-06 Array Biopharma Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
KR102244553B1 (ko) 2013-08-23 2021-04-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 용량 소자 및 반도체 장치
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
KR102379517B1 (ko) * 2013-12-30 2022-03-25 제넨테크, 인크. 세린/트레오닌 키나아제 억제제
CA2934709C (en) * 2013-12-30 2022-08-30 Array Biopharma Inc. Serine/threonine kinase inhibitors
MX2016013162A (es) * 2014-04-09 2017-04-27 Genentech Inc Proceso para la fabricacion de medicamentos.

Also Published As

Publication number Publication date
WO2013130976A1 (en) 2013-09-06
EP2820009B1 (en) 2018-01-31
NZ700314A (en) 2016-08-26
AU2013225737B2 (en) 2018-03-01
PH12014501947A1 (en) 2014-11-24
JP2015508828A (ja) 2015-03-23
RU2650501C2 (ru) 2018-04-16
JP2016027053A (ja) 2016-02-18
SI2820009T1 (en) 2018-05-31
HRP20180591T1 (hr) 2018-05-18
MX2014010432A (es) 2015-02-04
PH12015501654A1 (en) 2017-04-10
PL3321262T3 (pl) 2021-06-28
IL244276A0 (en) 2016-04-21
PT2820009T (pt) 2018-04-12
CR20140413A (es) 2014-11-05
EP2820009A1 (en) 2015-01-07
CN104507926B (zh) 2016-08-31
PT3321262T (pt) 2021-03-04
US9708290B2 (en) 2017-07-18
US10519126B2 (en) 2019-12-31
LT2820009T (lt) 2018-05-10
ZA201406688B (en) 2017-08-30
HK1254429A1 (zh) 2019-07-19
PH12015501654B1 (en) 2017-04-10
HUE053994T2 (hu) 2021-08-30
NO2945854T3 (es) 2018-07-21
US9259470B2 (en) 2016-02-16
UA116774C2 (uk) 2018-05-10
CN106349217A (zh) 2017-01-25
BR112014021634B1 (pt) 2022-09-27
CN104507926A (zh) 2015-04-08
DK2820009T3 (en) 2018-04-16
HK1206011A1 (en) 2015-12-31
PH12014501947B1 (en) 2014-11-24
ES2857649T3 (es) 2021-09-29
BR112014021634A8 (pt) 2018-01-30
RS57097B1 (sr) 2018-06-29
LT3321262T (lt) 2021-06-10
PH12015501653A1 (en) 2017-04-10
HK1204323A1 (en) 2015-11-13
HUE037423T2 (hu) 2018-08-28
EP3321262B1 (en) 2021-01-13
JP6068515B2 (ja) 2017-01-25
DK3321262T3 (da) 2021-01-25
IL234376A (en) 2016-10-31
US20160122316A1 (en) 2016-05-05
CY1120172T1 (el) 2018-12-12
ES2665073T3 (es) 2018-04-24
SG11201405356QA (en) 2014-11-27
CL2014002301A1 (es) 2015-05-08
SI3321262T1 (sl) 2021-04-30
US8697715B2 (en) 2014-04-15
CN106349217B (zh) 2020-08-28
US20140249127A1 (en) 2014-09-04
CO7081155A2 (es) 2014-10-10
EP3321262A1 (en) 2018-05-16
RS61500B1 (sr) 2021-03-31
KR102093526B1 (ko) 2020-03-25
CA2866086C (en) 2020-06-09
AR090220A1 (es) 2014-10-29
MY191936A (en) 2022-07-19
US20180127393A1 (en) 2018-05-10
TWI589569B (zh) 2017-07-01
TW201339146A (zh) 2013-10-01
US20130252934A1 (en) 2013-09-26
HRP20210482T1 (hr) 2021-05-14
KR20140138820A (ko) 2014-12-04
CA2866086A1 (en) 2013-09-06
ZA201508847B (en) 2023-01-25
RU2014139601A (ru) 2016-04-20
PH12015501653B1 (en) 2017-04-10
PL2820009T3 (pl) 2018-09-28
MX354675B (es) 2018-03-15
AR121879A2 (es) 2022-07-20
IL244276B (en) 2020-01-30

Similar Documents

Publication Publication Date Title
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
UY39630A (es) Inhibidores de bromodominios
ECSP18083519A (es) Inhibidores de bromodominios
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
PE20150669A1 (es) Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CR20160035A (es) Inhibidores de bromodominios
CO7180199A2 (es) Imidazotriazincarbonitrilos útiles como inhibidores de cinasa
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
ECSP12012083A (es) Pirrolidina-2-carboxamidas sustituidas
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
IN2015DN00185A (es)
IN2015DN00598A (es)
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
CR20130024A (es) Compuestos heterocíclicos fusionados
MX368178B (es) Compuestos de ácido dimetilbenzoico.
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
GB201209587D0 (en) Therapeutic compounds
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos

Legal Events

Date Code Title Description
FG Grant, registration